Date:12/14/2007

k that the Company will not have another opportunity to apply for a DTRA or other federal contract or the risk that, if able to apply, the Company may not be successful in negotiating a contract. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and the quarterly report on Form 10-Q for the quarter ended October 31, 2007. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Contacts:

GendeLLindheim BioCom Partners

Investors

info@peregrineinc.com

(800) 987-8256

Media

Barbara Lindheim

(212) 918-4650

'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. SportCoatings; The North American Booster Club Association (NABCA); the Coatings Specialist Group New Booster Program Goes High Tech With Invisible Antimicrobial Defense
2. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
3. CHS Receives Prestigious Honor from Department of Defense
4. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
5. Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development
6. Implicit Awarded US $16.3 Million U.S. Government Contract to Develop Immunomodulatory Drug for Biodefense Threats
7. ICx Awarded Department of Defense Contract for AirSentinel Monitors
8. Taming the anthrax threat
9. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
10. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
11. Taming the anthrax threat